News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Icon Bioscience Achieves Key Milestone With IBI-10090 Advancing Through Phase 3 Studies; Drug Targets Medical Need For Long-Acting Treatment Of Inflammation Post Cataract Surgery


5/6/2014 10:24:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SUNNYVALE, Calif.--(BUSINESS WIRE)--Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today reported that IBI-10090, the Company’s lead pipeline product, is in a pivotal Phase 3 study as a sustained-release therapy for inflammation associated with cataract surgery.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Cataract

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES